America Great Health is a small, early-stage holding company focused on health and biotech investments, primarily in the Asia Pacific region. The company does not generate meaningful revenue and operates through a collection of nascent ventures. In biotech, the company holds a 60% stake in a Hainan, China joint venture pursuing stem cell product R&D and sales, using patented technology contributed by partner Brilliant Healthcare. Through its 75%-owned subsidiary GOF Biotechnologies, the company is developing anti-cancer protein peptides and oral insulin based on licensed technology, with several patents pending. The company also holds a 51% equity stake in Purecell Group, an Australian anti-aging medical institution, though it does not exercise significant operational control over Purecell. A wholly-owned subsidiary, Nutrature Health, has indicated intentions in supplements manufacturing, though this business has no described operations. The company's model is to acquire or invest in health-related businesses and technologies, then develop early-stage products toward commercialization or licensing. Potential future revenue could come from product sales, investment returns, or licensing of drug technologies at clinical trial stages. With only 5 full-time employees, the company relies heavily on independent contractors and has funded its activities primarily through equity issuance.